Advanced Science (Apr 2022)
Identification of a STIM1 Splicing Variant that Promotes Glioblastoma Growth
- Jiansheng Xie,
- Guolin Ma,
- Lijuan Zhou,
- Lian He,
- Zhao Zhang,
- Peng Tan,
- Zixian Huang,
- Shaohai Fang,
- Tianlu Wang,
- Yi‐Tsang Lee,
- Shufan Wen,
- Stefan Siwko,
- Liuqing Wang,
- Jindou Liu,
- Yangchun Du,
- Ningxia Zhang,
- Xiaoxuan Liu,
- Leng Han,
- Yun Huang,
- Rui Wang,
- Youjun Wang,
- Yubin Zhou,
- Weidong Han
Affiliations
- Jiansheng Xie
- Department of Medical Oncology Laboratory of Cancer Biology Institute of Clinical Science Sir Run Run Shaw Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
- Guolin Ma
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Lijuan Zhou
- Beijing Key Laboratory of Gene Resource and Molecular Development College of Life Sciences Beijing Normal University Beijing 100875 P. R. China
- Lian He
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Zhao Zhang
- MOE Key Laboratory of Metabolism and Molecular Medicine Department of Biochemistry and Molecular Biology School of Basic Medical Sciences Fudan University Shanghai China
- Peng Tan
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Zixian Huang
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Shaohai Fang
- Center for Epigenetics and Disease Prevention Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Tianlu Wang
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Yi‐Tsang Lee
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Shufan Wen
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Stefan Siwko
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Liuqing Wang
- Beijing Key Laboratory of Gene Resource and Molecular Development College of Life Sciences Beijing Normal University Beijing 100875 P. R. China
- Jindou Liu
- Beijing Key Laboratory of Gene Resource and Molecular Development College of Life Sciences Beijing Normal University Beijing 100875 P. R. China
- Yangchun Du
- Beijing Key Laboratory of Gene Resource and Molecular Development College of Life Sciences Beijing Normal University Beijing 100875 P. R. China
- Ningxia Zhang
- Department of Medical Oncology Laboratory of Cancer Biology Institute of Clinical Science Sir Run Run Shaw Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
- Xiaoxuan Liu
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Leng Han
- Department of Biochemistry and Molecular Biology University of Texas Health Science Center at Houston McGovern Medical School Houston TX 77030 USA
- Yun Huang
- Center for Epigenetics and Disease Prevention Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Rui Wang
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Youjun Wang
- Beijing Key Laboratory of Gene Resource and Molecular Development College of Life Sciences Beijing Normal University Beijing 100875 P. R. China
- Yubin Zhou
- Center for Translational Cancer Research Institute of Biosciences and Technology Texas A&M University Houston TX 77030 USA
- Weidong Han
- Department of Medical Oncology Laboratory of Cancer Biology Institute of Clinical Science Sir Run Run Shaw Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
- DOI
- https://doi.org/10.1002/advs.202103940
- Journal volume & issue
-
Vol. 9,
no. 11
pp. n/a – n/a
Abstract
Abstract Deregulated store‐operated calcium entry (SOCE) mediated by aberrant STIM1‐ORAI1 signaling is closely implicated in cancer initiation and progression. Here the authors report the identification of an alternatively spliced variant of STIM1, designated STIM1β, that harbors an extra exon to encode 31 additional amino acids in the cytoplasmic domain. STIM1β, highly conserved in mammals, is aberrantly upregulated in glioma tissues to perturb Ca2+ signaling. At the molecular level, the 31‐residue insertion destabilizes STIM1β by perturbing its cytosolic inhibitory domain and accelerating its activation kinetics to efficiently engage and gate ORAI calcium channels. Functionally, STIM1β depletion affects SOCE in glioblastoma cells, suppresses tumor cell proliferation and growth both in vitro and in vivo. Collectively, their study establishes a splicing variant‐specific tumor‐promoting role of STIM1β that can be potentially targeted for glioblastoma intervention.
Keywords